NOV 12, 2015 9:00 AM PST

Use of a CD200R Inhibitor to Overcome Central Nervous System Tumor Induced Immunosuppression

Speaker
  • Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Minnesota
    BIOGRAPHY

Abstract

Cancer immunotherapy has demonstrated promising results. However, to date, researchers have failed to overcome the complex interplay between the immune system and the immune suppressive tumor microenvironment. Progression to a productive immune response involves passing a number of immunological checkpoints, which act as barriers for productive immunotherapies. To overcome this limitation, the FDA-approved monoclonal antibodies, ipilimumab, pembrolizumab and nivolumab, respectively, which inhibits the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD1) and programmed death 1 ligand (PD-L1) checkpoints. Both anti-CTLA4 and anti-PD1 act directly on T cells. In contrast, a third immunological checkpoint act directly on antigen presenting cells inducing T-cell tolerance. This checkpoint arises from the engagement of CD200 and it’s receptor (CD200R). CD200 is expressed in a variety of human tumors including melanoma and glioblastomas. However, it is the soluble form of CD200 that correlates with poor patient outcome. We reported that CD200 concentration significantly increased in the sera of glioma patients as their tumors progressed, which correlated with increased lineage negative myeloid derived suppressor cell (MDSC) population. We developed an inhibitor of the CD200 (CD200R antagonist) that acts directly on the CD200R on antigen presenting cells overpowering the suppressive properties of CD200. Our CD200R antagonist inhibits myeloid derived suppressor cell expansion, enhances cytokine and chemokine production significantly enhancing survival in both glioma and breast carcinoma tumor models.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
NOV 12, 2015 9:00 AM PST

Use of a CD200R Inhibitor to Overcome Central Nervous System Tumor Induced Immunosuppression


No demographic data is available yet for this event.


Show Resources
Loading Comments...
Show Resources